Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

BACKGROUND: Therapeutic cancer vaccines represent a promising approach to improve clinical outcomes with immune checkpoint inhibition. UV1 is a second generation telomerase-targeting therapeutic cancer vaccine being investigated across multiple indications. Although telomerase is a near-universal tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellingsen, Espen Basmo, Aamdal, Elin, Guren, Tormod, Lilleby, Wolfgang, Brunsvig, Paal F, Mangsbo, Sara M, Aamdal, Steinar, Hovig, Eivind, Mensali, Nadia, Gaudernack, Gustav, Inderberg, Else Marit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134181/
https://www.ncbi.nlm.nih.gov/pubmed/35613827
http://dx.doi.org/10.1136/jitc-2021-004345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134181/
https://www.ncbi.nlm.nih.gov/pubmed/35613827
http://dx.doi.org/10.1136/jitc-2021-004345

Ejemplares similares